Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 5/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 3/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9512291 | 1.00 | ESR2 (0.39) | ESR2AAK1PAX8NR3C1KDM1A | |
| SCHEMBL12230852 | 1.00 | ESR2 (0.39) | ESR2AAK1PAX8NR3C1KDM1A | |
| SCHEMBL21165799 | 0.88 | ESR2 (0.37) | ESR2KDM1A | |
| SCHEMBL9511367 | 0.88 | ESR2 (0.37) | ESR2KDM1A | |
| SCHEMBL23618045 | 0.86 | ACACB (0.33) | AAK1PAX8 | |
| SCHEMBL9512315 | 0.86 | ACACB (0.33) | AAK1PAX8 | |
| SCHEMBL9509427 | 0.84 | ESR2 (0.35) | ESR2PDE4A | |
| SCHEMBL9509449 | 0.84 | CYP2C9 (0.41) | ESR2AAK1PAX8S1PR1 | |
| SCHEMBL9512298 | 0.83 | RAB9A (0.38) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12892509 | 0.83 | ESR2 (0.41) | ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024017812-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2024-01-25 | — | — | WO | disclosed |
| WO-2021134883-A1 | LIQUID CRYSTAL COMPOSITION OF NEGATIVE LIQUID CRYSTAL COMPOUND HAVING METHOXY BRIDGE BOND AND USE THEREOF | 北京八亿时空液晶科技股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-9737854-B2 | Process for the purification of a liquid-crystal mixture | MERCK PATENT GMBH (DE) | 2017-08-22 | — | — | US | disclosed |
| US-9714381-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2017-07-25 | — | — | US | disclosed |
| US-20170044436-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| US-8129002-B2 | Compounds for use in liquid crystal media | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8043671-B2 | Liquid-crystalline medium and liquid crystal display | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-7824745-B2 | Benzochromene derivatives | MERCK PATENT GMBH (DE) | 2010-11-02 | — | — | US | disclosed |
| US-7678929-B2 | Furochroman derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-03-16 | — | — | US | disclosed |
| US-7531106-B2 | Mesogenic compounds, medium for electro-optical displays and electro-optical display | MERCK PATENT GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20090023802-A1 | Benzochromene Derivatives | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| US-7462297-B2 | Chiral dopants having a laterally alkylated phenyl structural element | MERCK PATENT GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7440160-B2 | Electro-optical light modulating element, electro-optical display and modulating medium | MERCK PATENT GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20080177095-A1 | FUROCHROMAN DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177095-A1 | FUROCHROMAN DERIVATIVES | CFD, LMAN1, UROD | ESR2 1410/4885AAK1 3514/4885PAX8 344/4885 |
| US-20090023802-A1 | Benzochromene Derivatives | SBDS, CRY1, DDT | ESR2 742/4885AAK1 2190/4885PAX8 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.